Over the past 12 months, shares of Amarin (AMRN 2.21%) have dropped 45% amid uncertainty around Vascepa's NCE status, buyout speculation that never came to fruition, and question marks around the efficacy of fish oil. The company is hoping to get expanded approval for Vascepa and announced today that the FDA's advisory committee meeting date has been set. In the following video, health-care analyst Max Macaluso discusses the importance of this meeting and the risks and opportunities up ahead for this speculative biotech.
S&P 500
5,970.37
+0.6%
+$34.43
DJI
42,519.64
+0.5%
+$214.16
NASDAQ
19,398.96
+0.8%
+$156.34
Bitcoin
105,405.00
+0.2%
+168.39
AAPL
$203.38
+0.8%
+$1.68
AMZN
$205.89
-0.4%
-$0.76
GOOG
$167.85
-1.5%
-$2.52
META
$667.31
-0.5%
-$3.59
MSFT
$463.24
+0.3%
+$1.28
NVDA
$141.38
+2.9%
+$4.00
TSLA
$344.95
+0.7%
+$2.26
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.